Literature DB >> 18709672

SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson's disease.

Pablo Martinez-Martin1, Martine Visser, Carmen Rodriguez-Blazquez, Johan Marinus, K Ray Chaudhuri, Jacobus J van Hilten.   

Abstract

This study evaluated the comparative validity and usefulness of the Parkinson's Disease Sleep Scale (PDSS) and the Scales for Outcomes in PD-Sleep Scale (SCOPA-S), two disease-specific rating scales for assessing sleep disorders in Parkinson's disease (PD). Hoehn and Yahr staging (HY), SCOPA-Motor, Mini-Mental State Examination, Clinical Impression of Severity Index for PD, Hospital Anxiety and Depression Scale, EuroQoL, and SCOPA-Psychosocial, in addition to PDSS and SCOPA-S (night-time sleep (NS) and daytime sleepiness (DS) subscales), were applied to 187 consecutive PD patients. PDSS and SCOPA-S proved similar in acceptability, scaling assumptions, precision, and internal consistency (Cronbach's alpha = 0.82-0.84). Factor analysis revealed five separate factors for PDSS (67% of the variance) and one factor for each SCOPA-S subscale (60% of the variance for NS and 57% for DS). Correlation coefficient between PDSS and SCOPA-S NS was -0.60. Sleep scales correlated moderately with mood, low-to-moderate with HRQoL, and low with the rest of measures. PDSS and SCOPA-S DS discriminated between patients grouped by HY severity levels and disease duration. Cutoff points of 82/83 for PDSS and 6/7 for SCOPA-S NS were drawn to identify PD patients with sleep problems. Depression/anxiety scores explained 26% for PDSS and 22% for SCOPA-S NS scores. Both scales provide valid, reliable, and useful means to evaluate sleep disorders in PD. PDSS may be used to obtain a profile about potential causes of "bad sleep," but is barely useful to assess DS, whereas SCOPA-S assesses nocturnal sleep disorders and daytime somnolence at a similar extent, without exploring the potential causes. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18709672     DOI: 10.1002/mds.22110

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease.

Authors:  Marta Kaminska; Victoria P Mery; Anne-Louise Lafontaine; Ann Robinson; Andrea Benedetti; Priti Gros; R John Kimoff
Journal:  J Clin Sleep Med       Date:  2018-05-15       Impact factor: 4.062

2.  Cross-cultural adaptation and psychometric properties of the SCOPA-Sleep-German version.

Authors:  Simone Goebel; Elisabeth Steinmann; Bernd Leplow; H Maximilian Mehdorn
Journal:  Neurol Sci       Date:  2018-04-14       Impact factor: 3.307

Review 3.  Sleep in Parkinson's Disease with Impulse Control Disorder.

Authors:  Michela Figorilli; Patrizia Congiu; Rosa Lecca; Gioia Gioi; Roberto Frau; Monica Puligheddu
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-11       Impact factor: 5.081

Review 4.  Disturbances of Sleep and Alertness in Parkinson's Disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-19       Impact factor: 5.081

5.  A Neurodegenerative Disease Sleep Questionnaire: principal component analysis in Parkinson's disease.

Authors:  Michael K Scullin; Tyler L Harrison; Stewart A Factor; Donald L Bliwise
Journal:  J Neurol Sci       Date:  2013-09-12       Impact factor: 3.181

Review 6.  A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.

Authors:  Lama M Chahine; Amy W Amara; Aleksandar Videnovic
Journal:  Sleep Med Rev       Date:  2016-08-31       Impact factor: 11.609

7.  Pimavanserin use in a movement disorders clinic: a single-center experience.

Authors:  Abhimanyu Mahajan; Bisena Bulica; Ayesha Ahmad; Patricia Kaminski; Peter LeWitt; Danette Taylor; Shana Krstevska; Neepa Patel
Journal:  Neurol Sci       Date:  2018-07-21       Impact factor: 3.307

8.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

9.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

10.  The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls.

Authors:  Peter Hagell; Albert Westergren; Shorena Janelidze; Oskar Hansson
Journal:  Qual Life Res       Date:  2016-05-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.